40 related articles for article (PubMed ID: 21630531)
1. Monobactam formation in sulfazecin by a nonribosomal peptide synthetase thioesterase.
Oliver RA; Li R; Townsend CA
Nat Chem Biol; 2018 Jan; 14(1):5-7. PubMed ID: 29155429
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections.
Tan L; Tao Y; Wang T; Zou F; Zhang S; Kou Q; Niu A; Chen Q; Chu W; Chen X; Wang H; Yang Y
J Med Chem; 2017 Apr; 60(7):2669-2684. PubMed ID: 28287720
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of C(4) substituted monobactams as antibacterial agents against multidrug-resistant Gram-negative bacteria.
Kou Q; Wang T; Zou F; Zhang S; Chen Q; Yang Y
Eur J Med Chem; 2018 May; 151():98-109. PubMed ID: 29605810
[TBL] [Abstract][Full Text] [Related]
4. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli.
Page MG; Dantier C; Desarbre E
Antimicrob Agents Chemother; 2010 Jun; 54(6):2291-302. PubMed ID: 20308379
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of monobactams as antibacterial agents against gram-negative bacteria.
Fu HG; Hu XX; Li CR; Li YH; Wang YX; Jiang JD; Bi CW; Tang S; You XF; Song DQ
Eur J Med Chem; 2016 Mar; 110():151-63. PubMed ID: 26827160
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens.
Hornsey M; Phee L; Stubbings W; Wareham DW
Int J Antimicrob Agents; 2013 Oct; 42(4):343-6. PubMed ID: 23837926
[TBL] [Abstract][Full Text] [Related]
7. [BAL30072--an iron complexing beta lactam antibiotic against multidrug-resistant gram negative bacteria].
Schmitz J
Pharm Unserer Zeit; 2011 Mar; 40(2):98-9. PubMed ID: 21630531
[No Abstract] [Full Text] [Related]
8. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
Falagas ME; Mavroudis AD; Vardakas KZ
Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial and β-Lactamase Inhibitory Activity of Monocyclic β-Lactams.
Decuyper L; Jukič M; Sosič I; Žula A; D'hooghe M; Gobec S
Med Res Rev; 2018 Mar; 38(2):426-503. PubMed ID: 28815732
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria.
Tang SS; Apisarnthanarak A; Hsu LY
Adv Drug Deliv Rev; 2014 Nov; 78():3-13. PubMed ID: 25134490
[TBL] [Abstract][Full Text] [Related]
11. Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
Koulenti D; Song A; Ellingboe A; Abdul-Aziz MH; Harris P; Gavey E; Lipman J
Int J Antimicrob Agents; 2019 Mar; 53(3):211-224. PubMed ID: 30394301
[TBL] [Abstract][Full Text] [Related]
12. New β-lactam antibiotics and β-lactamase inhibitors.
Bush K; Macielag MJ
Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
